within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX24_Surufatinib;
model Surufatinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EX24;

  annotation(Documentation(
    info ="<html><body><p>Surufatinib is an oral small molecule tyrosine kinase inhibitor targeting VEGFR, FGFR1, and CSF-1R. It is developed for the treatment of neuroendocrine tumors (NETs) and has received approval in China for the treatment of non-pancreatic neuroendocrine tumors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for adult patients with advanced solid tumors, typically Asian (Chinese) individuals. Data most extensively reported for the oral administration of surufatinib at steady state.</p><h4>References</h4><ol><li><p>Lu, X, et al., &amp; Chen, Z (2021). Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. <i>Expert review of anticancer therapy</i> 21(9) 917–926. DOI:<a href=&quot;https://doi.org/10.1080/14737140.2021.1944110&quot;>10.1080/14737140.2021.1944110</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34142932/&quot;>https://pubmed.ncbi.nlm.nih.gov/34142932</a></p></li><li><p>Xu, J (2021). Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). <i>Therapeutic advances in medical oncology</i> 13 17588359211042689–None. DOI:<a href=&quot;https://doi.org/10.1177/17588359211042689&quot;>10.1177/17588359211042689</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34484432/&quot;>https://pubmed.ncbi.nlm.nih.gov/34484432</a></p></li><li><p>Li, K, et al., &amp; Sai, Y (2020). Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans. <i>Current drug metabolism</i> 21(5) 357–367. DOI:<a href=&quot;https://doi.org/10.2174/1389200221666200514131721&quot;>10.2174/1389200221666200514131721</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32407271/&quot;>https://pubmed.ncbi.nlm.nih.gov/32407271</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Surufatinib;
